AGIC-CAPITAL
30.11.2022 08:01:41 CET | Business Wire | Press release
AGIC Capital ("AGIC"), a growth-oriented private equity firm with $2.2 billion of assets under management, today announced that it had acquired a majority stake in ATEC Pharmatechnik GmbH ("ATEC" or "the Company"). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the Company, and Hans-Werner Mumm will continue to act as its CEO.
ATEC is a leading manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies. ATEC's products include stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bag solutions. These mission-critical technologies enable ATEC's customers to establish safe and reliable manufacturing process environments.
This is anticipated to be the first of several acquisitions as AGIC builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.
Hans-Werner Mumm, CEO of ATEC commented, "We are excited to partner with AGIC, a firm that shares our passion for providing our customers with safer aseptic transfer technologies, which are critical to the future of medicine. We look forward to expanding our critical role in pharmaceutical manufacturing and bioprocessing as we invest in our next phase of growth."
Erik Yankulin, Managing Director at AGIC, added, "ATEC supports the production of life-saving therapies by providing best-in-class aseptic transfer technologies to pharmaceutical and biopharmaceutical companies. Specifically, the Company's products provide industry-leading solutions for handling sterile drug products across the most demanding pharmaceutical manufacturing applications in the areas of diabetes, oncology and other therapies. We are excited to support ATEC through investments into new product development, go-to-market capabilities, and add-on acquisitions."
Frank Löffler, Partner at HANNOVER Finanz added, “We have worked closely with Hans-Werner and ATEC’s management team since 2018 to grow the business, its customer base and innovative product offering. We strongly believe in the company’s potential and wish AGIC as the future majority shareholder the best of success in driving the next chapter of ATEC’s growth.”
ATEC and HANNOVER Finanz were advised by Macquarie Capital with Latham & Watkins LLP advising the sellers, while AGIC was supported by White & Case LLP in connection with the acquisition.
About AGIC Capital
AGIC is a growth-oriented private equity firm that seeks to invest in thriving middle-market businesses focused on advanced industrial and healthcare technologies in Europe & beyond. AGIC’s differentiated investment strategy combines deep business model expertise, proactive thematic research, an unrelenting focus on the upside and a collaborative, management-first approach to value creation. Launched in 2015, AGIC currently has $2.2 billion in assets under management. The firm's more than 25 professionals are based in Europe and Asia. For more information about AGIC's investment philosophy, visit www.agic-group.com.
About ATEC Pharmatechnik GmbH
ATEC Pharmatechnik GmbH is a leader in stopper and cap processing solutions used for aseptic filling with patented process technology in pharmaceutical applications. ATEC’s products are used primarily in pharmaceutical manufacturing and bioprocessing applications and comprise stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bags and spare parts. The Company is headquartered in Sörup, Germany. www.atecgroup.de
About HANNOVER Finanz
HANNOVER Finanz Group has been a sought-after private equity partner for medium sized enterprises in all industries for more than 40 years now. The private equity firm is based in Hanover and Vienna and was founded in 1979 as one of the first providers of venture capital in Germany. Currently, the HANNOVER Finanz Group has over 700 million Euros of assets under management across around 40 companies in Germany and Austria. Since its foundation, the Group has invested an accumulated total of over one and a half billion Euros and has successfully completed more than 250 projects. For more information, please visit www.hannoverfinanz.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005602/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom